Substituts des globules rouges: émulsions de fluorocarbures et solutions d'hémoglobine

[en] OBJECTIVE: To review the current data on perfluorocarbon (PFC) emulsions and haemoglobin (Hb) solutions. DATA SOURCES: For this paper we analysed the literature using Medline search along with major review articles. DATA SELECTION AND EXTRACTION: The collected articles were reviewed and selected according to their quality and originality. DATA SYNTHESIS: PFCs are synthetic fluorinated hydrocarbons capable of dissolving, at increased FIO2, large amounts of oxygen. They deliver oxygen at tissular level, and are administered as emulsions containing particles of around 0.1 micron, reaching the smallest vessels. They are exhaled unchanged by the lungs within 7 days. The first clinically used PFC was Fluosol-DA 20%. Currently, Oxyfluor 40% and Oxygent 60% are under evaluation. PFCs are not true blood substitutes, but rather a means to support tissue oxygenation during extreme haemodilution. Solutions of free Hb do not require compatibility testing and are fully saturated with oxygen at ambient FIO2. Hb is either human, bovine or recombinant Hb. In order to maintain adequate intravascular half-life and affinity for oxygen, the Hb molecules are modified by internal cross-linking, polymerisation and encapsulation. After promising results using animal models, some of these modified Hb solutions are now undergoing phase III clinical trials. Among these, diaspirin cross-linked haemoglobin (DCLHb) has been tested in cardiac and orthopaedic surgery, as well as in trauma patients. The initial results of these multicentre trials are currently being analysed.

Disciplines :

Human health sciences: Multidisciplinary, general & others
Anesthesia & intensive care

Author, co-author :

Remy, Bernadette ; Centre Hospitalier Universitaire de Liège - CHU > Anesthésie et réanimation

Deby, Ginette ; Université de Liège - ULiège > Centre de l'oxygène : Recherche et développement (C.O.R.D.)

D'Ans, V.

Ernest, Philippe ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques

Lamy, Maurice ; Université de Liège - ULiège > Département des sciences cliniques > Anesthésie et réanimation

Language :

French

Title :

Substituts des globules rouges: émulsions de fluorocarbures et solutions d'hémoglobine

Alternative titles :

[en] Red Cell Substitutes: Perfluorocarbon Emulsions and Hemoglobin Solutions

Publication date :

February 1999

Journal title :

Annales Françaises d'Anesthésie et de Réanimation

ISSN :

0750-7658

eISSN :

1769-6623

Publisher :

Elsevier, Paris, France

Volume :

Issue :

Pages :

211-24

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 25 March 2009

Statistics

Number of views

92 (8 by ULiège)

Number of downloads

3 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Baron JF, Mouren S. Substituts érythrocytaires. In: Baron JF, Samama CM, eds. Hémodilution. Autotransfusion. Hémostase. Paris: Arnette; 1989. p. 137-42.
Jones JA. Red blood cell substitutes: current status. Br J Anaesth 1995 ; 74 : 697-703.
Dietz NM, Joyner MJ, Warner MA. Blood substitutes: fluids, drugs, or miracle solutions? Anesth Analg 1996 ; 82 : 390-405.
Winslow RM. Blood Substitutes. Sci Med 1997 ; 4 : 54-63.
Valbonesi M, Bruni R, Giannini G, Florio G. Blood substitutes: is it time for work process redesign in transfusion medicine [abstract]? Anaesthesia 1998 ; 53 Suppl 2 : 26.
Habler O, Kleen M, Messmer K. Clinical potential of intravenously administered perfluorocarbons. Acta Anaesthesiol Scand 1997 ; 41 Suppl 111 : 256-8.
Lattes A, Rico-Lattes I. Microemulsions of perfluorinated and semi-fluorinated compounds. Artif Cells Blood Substit Immobil Biotechnol 1994 ; 22 Suppl 4 : 1007-8.
Ohyanagi H, Saitoh Y. Development and clinical application of perfluorochemical artificial blood. Int J Artif Organs 1986 ; 9 : 363-8.
Spence RK. Perfluorocarbons in the twenty-first century: clinical applications as transfusion alternatives. Artif Cell Blood Substit 1995 ; 23 : 367-80.
Wade EL, Eddy LJ, Green D, Radin AI. Fluosol in the treatment of sickle cell crisis. Transfus Sci 1996 ; 17 : 309-13.
Meinert H, Fackler R, Knoblich A, Mader J, Reuter P, Rohlke W. On the perfluorocarbon emulsions of second generation. Biomater Artif Cells Immobilization Biotechnol 1992 ; 20 : 805-18.
Kaufman RJ. Clinical development of perfluorocarbon-based emulsions as red cell substitutes. In: Winslow RM, Vandegriff KD, Intaglietta M, eds. Blood Substitutes: physiological basis of efficacy. Boston: Birkhaüser; 1995. p. 53-74.
Wahr JA, Trouwborst A, Spence RK, Henny CP, Cernaianu AC, Graziano GP, et al. A pilot study of the effects of a perflubron emulsion, AF 0104, on mixed venous oxygen tension in anesthetized surgical patients. Anesth Analg 1996 ; 82 : 103-7.
Goodin TH, Grossbard EB, Kaufman RJ, Richard TJ, Kolata RJ, Allen JS, et al. A perfluorochemical emulsion for prehospital resuscitation of experimental hemorrhagic shock: a prospective, randomized controlled study. Crit Care Med 1994 ; 22 : 680-9.
Ogilby JD. Cardiovascular applications of fluorocarbons: current status and future direction - a critical clinical appraisal. Artif Cells Blood Substit Immobil Biotechnol 1994 ; 22 : 1083-96.
Lachmann B, Verbrugge S. Liquid ventilation. Curr Opin Crit Care 1996 ; 2 : 60-6.
Leach CL, Greenspan JS, Rubenstein SD, Shaffer TH, Wolfson MR, Jackson JC, et al. Partial liquid ventilation with perflubron in premature infants with severe respiratory distress syndrome. The LiquiVent study group. N Engl J Med 1996 ; 335 : 814-5.
Suit H. Tumor oxygenation and radiosensitivity. In: Winslow RM, Vandegriff KD, Intaglietta M, eds. Blood substitutes: physiological basis of efficacy. Boston: Birkhaüser; 1995. p. 187-99.
Tremper KK. Hemoglobin-based oxygen carriers: problems and promise [editorial]. J Cardiothorac Vasc Anesth 1997 ; 11 : 1-2.
Waschke KF, Frietsch T, Quintel M, Lenz C, Rebel A. Hemoglobin solutions. Acta Anaesthesiol Scand 1997 ; 41 Suppl 111 : 259-63.
Von Stark. Die Resorbarkeit des Haimatins und die Bedeutung der Hemoglobin - Preparate. Dtsch Med Wochenschr 1898 ; 24 : 805-8.
Sellards AW, Minot GR. Injection of hemoglobin in man and its relation to blood destruction with especial reference to the anemias. J Med Res 1916 ; 34 : 469-94.
Amberson WR. Blood Substitutes. Biol Rev 1937 ; 12 : 48-52.
Hess JR, MacDonald VW, Brinkley WW. Systemic and pulmonary hypertension after resuscitation with cell-free hemoglobin. J Appl Physiol 1993 ; 74 : 1769-78.
Amberson WR, Jennings JJ, Rhode CM. Clinical experience with hemoglobin - saline solutions. J Appl Physiol 1949 ; 1 : 469-89.
Rabiner SF, O'Brien K, Peskin GW, Friedmand LH. Further studies with stroma-free hemoglobin solution. Ann Surg 1970 ; 171 : 615-22.
Feola M, Simoni J, Tran R, Canizaro P. Mechanisms of toxicity of hemoglobin solutions. Biomater Artif Cells Artif Organs 1988 ; 16 : 217-26.
Lee R, Atsumi N, Jacobs EE Jr, Austen WG, Vlahakes GJ. Ultrapure, stroma-free, polymerized bovine hemoglobin solution: evaluation of renal toxicity. J Surg Res 1989 ; 47 : 407-11.
Krieter H, Hagen G, Waschke KF, Köhler A, Wenneis B, Brückner UB, et al. Isovolemic hemodilution with a bovine hemoglobin-based oxygen carrier: effects on hemodynamics and oxygen transport in comparison with a nonoxygen-carrying volume substitute. J Cardiothorac Vasc Anesth 1997 ; 11 : 3-9.
Monk T, Goodnough L, Hughes G Jr, Jacobs E Jr. Evaluation of the safety and tolerance of hemoglobin-based oxygen carrier-201 [abstract]. Anesthesiology 1995 ; 83 Suppl 3 : A285.
Feola M, Simoni J, Angelillo R, Luhruma Z, Kabakele M, Manzombi M, et al. Clinical trial of a hemoglobin based blood substitute in patients with sickle cell anemia. Surg Gynecol Obstet 1992 ; 174 : 379-86.
Hughes GS, Antal EJ, Locker PK, Francom SF, Adams WJ, Jacobs EE. Physiology and pharmacokinetics of a novel hemoglobin-based oxygen carrier in humans. Crit Care Med 1996 ; 24 : 756-64.
Hoffman SJ, Looker DL, Roehrich JM, Cozart PE, Durfee SL, Tedesco JL, et al. Expression of fully functional tetrameric human hemoglobin in Escherichia Coli. Proc Natl Acad Sci États-Unis 1990 ; 87 : 8521-5.
Looker D, Abbott-Brown D, Kozart P, et al. A human recombinant hemoglobin designed for use as a blood substitute. Nature 1992 ; 356 : 258-60.
Shoemaker SA, Gerber MJ, Evans GL, Archer-Paik LE, Scoggin CH. Initial clinical experience with a rationally designed genetically engineered recombinant human hemoglobin. Artif Cells Blood Substit Immobil Biotechnol 1994 ; 22 : 457-65.
Bunn HF, Jandl JH. Renal handling of hemoglobin. Catabolism. J Exp Med 1968 ; 129 : 925-34.
Yang T, Olsen KW. Thermal stability of hemoglobin crosslinked in the T-state by bis (3,5-dibromosalicyl) fumarate. Biochem Biophys Res Commun 1991 ; 174 : 518-23.
Benesch RE, Benesch R, Renthal RD, Maeda N. Affinity labeling of the polyphostate binding site of hemoglobin. Biochemistry 1972 ; 11 : 3576-82.
Klotz IM, Tam JWO. Acetylation of sickle cell hemoglobin by aspirin. Proc Natl Acad Sci États-Unis 1973 ; 70 : 1313-5.
Bridges KR, Schmidt GT, Jensen M, Cerami A, Bunn HF. The acetylation of hemoglobin by aspirin. In vitro and in vivo. J Clin Invest 1975 ; 56 : 201-7.
Walder JA, Zangg RH, Walder RY, Zaugg RH, Walder RY, Steele JM, et al. Diaspirins that cross-link beta chains of hemoglobin : bis(3,5-dibromosalicyl) succinate and bi (3,5-dibromosalicyl) fumarate. Biochem 1979 ; 20 : 4265-70.
Larsen RW, Chavez MD, Ondrias MR, Courtney SH, Friedman JM, Lin MJ, et al. Dynamics and reactivity of Hb XL 99 alpha. A cros-linked hemoglobin derivative. J Biol Chem 1990 ; 265 : 4449-54.
Przybelski RJ, Daily EK. The pressor/perfusion effect of diaspirin cross-linked hemoglobin (DCLHb). In: Vincent JL, ed. Yearbook of intensive care and emergency medicine. Berlin: Springer; 1994. p. 252-63.
Farmer M, Ebeling A, Marshall T, Hauck W, Sun CS, White E, et al. Validation of virus inactivation by heat treatment in the manufacture of diaspirin crosslinked hemoglobin. Biomater Artif Cells Immobilization Biotechnol 1992 ; 20 : 429-33.
Estep TN, Gonder J, Bornstein I, Aono F. Immunogenicity of diaspirin cross-linked human hemoglobin solutions. Biomater Artif Cells Immobilization Biotechnol 1992 ; 20 : 603-9.
Vandegriff KD, Medina F, Marini MA, Winslow RM. Equilibrium oxygen binding to human hemoglobin cross-linked between the alpha chains by bis (3,5-dibromosalicyl) fumarate. J Biol Chem 1989 ; 264 : 17824-33.
Vandegriff KD, Le Tellier YC, Winslow RM, Rohlfs RJ, Olson JS. Determination of the rate and equilibrium constants for oxygen and carbon monoxide binding to R-state human hemoglobin cross-linked between the alpha subunits at lysine 99. J Biol Chem 1991 ; 266 : 17049-59.
Vandegriff KD, Benazzi L, Ripamonti M, Perrella M, Le Tellier YC, Zegna YC, et al. Carbon dioxide binding to human hemoglobin cross-linked between the alpha chains. J Biol Chem 1991a ; 266 : 2697-700.
Malcolm D, Kissinger D, Garrioch M. Diaspirin cross-linked hemoglobin solution as a resuscitative fluid following severe hemorrhage in the rat. Biomater Artif Cells Immobilization Biotechnol 1992 ; 20 : 495-7.
Schultz SC, Powell CC, Burris DG, Nguyen H, Jaffin J, Malcolm DS. The efficacy of diaspirin crosslinked hemoglobin solution resuscitation in a model of uncontrolled hemorrhage. J Trauma 1994 ; 37 : 408-12.
Przybelski RJ, Malcolm DS, Burris DG, Winslow RM. Cross-linked hemoglobin solution as a resuscitative fluid after hemorrhage in the rat. J Lab Clin Med 1991 ; 117 : 143-51.
Hamilton I, Schultz S, Cole F, Burhop K, Malcom D. Characterization of diaspirin cross-linked hemoglobin's presser response [abstract]. Crit Care Med 1992 ; 20 : Suppl : S106.
Schultz SC, Grady B, Cole F, Hamilton I, Burhop K, Malcolm DS. A role of endothelin and nitric oxide in the presser response to diaspirin cross-linked hemoglobin. J Lab Clin Med 1993 ; 122 : 301-8.
Sharma AC, Rebello BS, Gulati A. Regional circulatory and systemic hemodynamic effects of diaspirin cross-linked hemoglobin in the rat. Artif Cells Blood Substit Immobil Biotechnol 1994; 22 Suppl 3: 593-602.
Gulati A, Rebello S. Diaspirin cross-linked hemoglobin (DCLHB): involvement of adrenergic mechanisms in the pressor effect. Artif Cells Blood Substit Immobil Biotechnol 1994 ; 22 : 603-12.
Gulati A, Rebello S. Role of adrenergic mechanisms in the presser effect of diasprin cross-linked hemoglobin. J Lab Clin Med 1994a ; 124 : 125-33.
Yates WG, Vincent GM, Witzel T, Tierstein PS, Przybelski RJ, Estep TW. Intracoronary diaspirin crosslinked hemoglobin (DCLHb) infusion during coronary balloon occlusion in dogs and pigs. Biomat Artif Cells Immobil Biotechnol 1991 ; 19.
McKenzie JE, Cost EA, Scandling DM, Ahle NW, Savage RW. Effects of diaspirin crosslinked haemoglobin during coronary angioplasty in the swine. Cardiovasc Res 1994 ; 28 : 1188-92.
Cole DJ, Schell RM, Przybelski RJ, Drummond JC, Bradley K. Focal cerebral ischemia in rats: effects of hemodilution with alpha-alpha cross-linked hemoglobin on CBF. J Cereb Blood Flow Metab 1992 ; 12 : 971-6.
Cole DJ, Drummond JC, Patel PM, Marcantonio S. Effects of viscosity and oxygen content on cerebral blood flow in ischemic and normal rat brain. J Neurol Sci 1994 ; 124 : 15-20.
Cole DJ, Przybelski RJ, Schell RM, Martin RD. Diaspirin crosslinked hemoglobin (DCLHB): effect of hemodilution during focal cerebral ischemia in rats. Artif Cells Blood Substit Immobil Biotechnol 1994a ; 22 : 813-8.
Cole DJ, Drummond JC, Patel PM, Reynolds LR. Hypervolemic-hemodilution during cerebral ischemia in rats: effect of diaspirin cross-linked hemoglobin (DCLHb) on neurologic outcome and infarct volume. J Neurosurg Anesthesiol 1997 ; 9 : 44-50.
Piper JR, Garrioch MA, Souter MJ, Andrews PJD, Thomson D. Effects of diaspirin cross-linked haemoglobin on post-traumatic cerebral perfusion pressure and blood flow in a rodent model of diffuse brain injury. Br J Anaesth 1998 ; 80 : 639-43.
Aranow JS, Wang H, Zhuang J, Fink MP. Effect of human hemoglobin on systemic and regional hemodynamics in a porcine model of endotoxemic shock. Crit Care Med 1996 ; 24 : 807-14.
Przybelski RJ, Daily EK, Kisicki JC, Mattia-Goldberg C, Bounds MJ, Colburn WA. Phase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solution. Crit Care Med 1996 ; 24 : 1993-2000.
Sloan EP, Koenigsberg MD, Bickell WH. The use of diaspirin cross-linked Hemoglobin solution in the hospital management of hemorrhagic hypovolemic shock [abstract]. Ann Emerg Med 1995 ; 2.
Lierneux B, Rémy B, Noirot D, Paris P, Lemaire R, Albassir A, et al. Evaluation of use of diaspirin cross-linked hemoglobin (DCLHb) solution in total hip remplacement (THR). Acta Anaesthesiol Belg 1997.
Garrioch M, Larbuisson R, Brichant JF, Lamy M, Daily E, Przybelski R. The hemodynamic effects of diaspirin cross-linked hemoglobin (DCLHb) in the operative setting [abstract]. Crit Care Med 1996 ; 24 Suppl : A39.
Swan SK, Halstenson CE, Collins AJ, Colburn WA, Blue J, Przybelski RJ. Pharmacologic profile of diaspirin cross-linked hemoglobin in hemodialysis patients. Am J Kidney Dis 1995 ; 26 : 918-23.
Reah G, Mallick A, Bodenham AR, Przybelski R. Diaspirin cross-linked hemoglobin improves gastric intramucosal pH in critically ill patients [abstract]. Intensive Care Med 1996 ; 22 Suppl 3 : S441.
Reah G, Bodenham A, Mallick A, Przybelski R, Daily E. Vasopressor effects of Diaspirin Cross-linked Hemoglobin (DCLHb) in critically ill patients [abstract]. Crit Care Med 1996 ; 24 Suppl 1 : A39.
Beissinger MC, Farmer RL, Gossage JL. Liposome encapsulated hemoglobin as a red cell surrogate. Trans An Soc Actif Intern Organs 1986 ; 32 : 58-63.
Rudolph AS. Encapsulation of hemoglobin in liposomes. In: Wuislow RM, Vandegriff KD, Intaglietta M, eds. Blood substitutes: physiological basis of efficacy. Boston: Birkhaüser; 1995. p. 90-104.
Rabinovici R, Rudolph AS, Vernicke J, Feuerstein G. A new salutary resuscitative fluid: liposome encapsulated hemoglobin/hypertonic saline solution. J Trauma 1993 ; 35 : 121-7.
Rudolph AS, Cliff RO, Spargo BJ, Spielberg H. Transient changes in the mononuclear phagocyte system following administration of the blood substitute, liposome-encapsulated haemoglobin. Biomaterials 1994 ; 15 : 796-804.
Wahr JA, Anderson MM, Giacherio DA, Hallock L, Gawryl MS, Lansden C, et al. The effects of a blood-salvaging device on blood containing a hemoglobin-based oxygen carrier, HBOC-201. J Cardiothorac Vasc Anesth 1997 ; 11 : 10-2.